Clinical Trial

A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will assess the adverse events and how oral ABBV-932 moves through the body when given with oral Itraconazole in adult participants with bipolar disorder.
Protocol Amendment History 3 changes
critical Trial status changed: Active, Not Recruiting → Not Yet Recruiting 2026-08-07
notable Primary completion pushed: 2025-11 -> 2027-02 2026-08-07
minor Completion pushed: 2025-11 -> 2027-02 2026-08-07
Trial Details
NCT Number NCT07071532
Lead Sponsor AbbVie
Conditions Bipolar Disorder
Enrollment 20 participants
Start Date 2026-08-21
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-06